What is the license age for the Menactra vaccine?

The Menactra vaccine, which is used to protect against meningococcal disease, has an approved age range for administration that reflects the groups at highest risk. The correct choice indicates that the vaccine is licensed for individuals ranging from 9 months to 55 years of age. This age range is crucial as it targets young children, adolescents, and young adults, who are at a higher risk of contracting meningococcal infections.

Understanding the licensed age for the Menactra vaccine is important for healthcare providers to ensure that vaccinations are administered appropriately to maximize immunization benefits in the population at risk. The range reflects both efficacy and safety evaluations conducted during clinical trials. Other age groups listed in the incorrect options do not cover the effective licensing standards set by health authorities for the Menactra vaccine, which is critical to highlight in immunization practices.